

2018

THE LEGISLATIVE ASSEMBLY  
FOR THE AUSTRALIAN CAPITAL TERRITORY

---

(As presented)

(Minister for Health and Wellbeing)

# Medicines, Poisons and Therapeutic Goods Amendment Bill 2018

## Contents

---

		Page
<b>Part 1</b>	<b>Preliminary</b>	
1	Name of Act	2
2	Commencement	2
3	Legislation amended	2
<b>Part 2</b>	<b>Medicines, Poisons and Therapeutic Goods Act 2008</b>	
4	Supply of certain declared substances—information for chief health officer Section 31 (1) (a) and (2) (a)	3

---

J2017-432

Authorised by the ACT Parliamentary Counsel—also accessible at [www.legislation.act.gov.au](http://www.legislation.act.gov.au)

## Contents

---

	Page	
5	New chapter 6A	3
6	Disciplinary action against authorisation holders Section 141 (1) (d)	9
7	New section 141 (1) (h)	9
8	Sections 144 (2) (b) and 145 (1) (b)	10
9	Section 145 (1) (c)	10
10	Action by chief health officer in relation to certain licences and approvals Section 146 (1)	10
11	Reviewable decisions Schedule 1, item 6, column 3, 4th dot point	11
12	Dictionary, new definitions	11
<b>Part 3</b>	<b>Medicines, Poisons and Therapeutic Goods Regulation 2008</b>	
13	Section 81	12
14	Section 164	13

2018

THE LEGISLATIVE ASSEMBLY  
FOR THE AUSTRALIAN CAPITAL TERRITORY

---

(As presented)

(Minister for Health and Wellbeing)

# Medicines, Poisons and Therapeutic Goods Amendment Bill 2018

---

## A Bill for

An Act to amend the *Medicines, Poisons and Therapeutic Goods Act 2008* and  
the *Medicines, Poisons and Therapeutic Goods Regulation 2008*

---

The Legislative Assembly for the Australian Capital Territory enacts as  
follows:

---

J2017-432

Authorised by the ACT Parliamentary Counsel—also accessible at [www.legislation.act.gov.au](http://www.legislation.act.gov.au)

1 **Part 1 Preliminary**

2 **1 Name of Act**

3 This Act is the *Medicines, Poisons and Therapeutic Goods*  
4 *Amendment Act 2018*.

5 **2 Commencement**

6 This Act commences on the day after its notification day.

7 *Note* The naming and commencement provisions automatically commence on  
8 the notification day (see [Legislation Act](#), s 75 (1)).

9 **3 Legislation amended**

10 This Act amends the *Medicines, Poisons and Therapeutic Goods*  
11 *Act 2008* and the *Medicines, Poisons and Therapeutic Goods*  
12 *Regulation 2008*.

---

1 **Part 2** **Medicines, Poisons and**  
2 **Therapeutic Goods Act 2008**

3 **4 Supply of certain declared substances—information for**  
4 **chief health officer**  
5 **Section 31 (1) (a) and (2) (a)**

6 *omit*

7 controlled medicine

8 *substitute*

9 monitored medicine

10 **5 New chapter 6A**

11 *insert*

12 **Chapter 6A Monitored medicines database**

13 **97A Meaning of *monitored medicine***

14 (1) In this Act:

15 *monitored medicine* means—

16 (a) a controlled medicine; or

17 (b) a medicine declared by the Minister to be a monitored  
18 medicine.

19 (2) For the definition of *monitored medicine*, paragraph (b), the  
20 Minister may declare a medicine to be a monitored medicine if  
21 satisfied that the declaration is consistent with the purposes of the  
22 monitored medicines database.

1 (3) A declaration under this section is a disallowable instrument.

2 *Note* A disallowable instrument must be notified, and presented to the  
3 Legislative Assembly, under the [Legislation Act](#).

#### 4 **97B Definitions—ch 6A**

5 In this chapter:

6 *another jurisdiction* means the Commonwealth or a State.

7 *Note* *State* includes the Northern Territory (see [Legislation Act](#), dict, pt 1).

8 *approved data source entity* means an entity engaged by another  
9 jurisdiction to collect, access, store or otherwise deal with  
10 information about monitored medicines.

11 *monitored medicines database*—see section 97D.

12 *relevant health practitioner* means a health practitioner authorised  
13 by regulation to prescribe or supply a monitored medicine.

14 *required information*, about the supply of a monitored medicine—  
15 see section 31 (4).

#### 16 **97C Monitored medicines database—purposes**

17 (1) The main purpose of the monitored medicines database is to  
18 promote and protect public health and safety by ensuring that  
19 information is available to—

20 (a) monitor and evaluate the supply of monitored medicines to a  
21 person; and

22 (b) support the exercise of the chief health officer’s functions.

23 (2) A regulation may prescribe additional purposes for the monitored  
24 medicines database.

- 1     **97D     Monitored medicines database—scope**
- 2             (1) The chief health officer may keep a database (the *monitored*
- 3             *medicines database*) to record information relating to monitored
- 4             medicines.
- 5             (2) The monitored medicines database may be kept in any form,
- 6             including electronically, that the chief health officer decides.
- 7             (3) The chief health officer may—
- 8                 (a) correct an error or omission in the monitored medicines
- 9                 database; and
- 10                (b) change information included in the database to keep the
- 11                database accurate and up-to-date.
- 12             (4) The monitored medicines database may include the following:
- 13                (a) required information about the supply of a monitored medicine
- 14                under a supply authority;
- 15                (b) information about the approval to prescribe a monitored
- 16                medicine;
- 17                (c) information from another jurisdiction in relation to the supply
- 18                or prescription of a monitored medicine in the other
- 19                jurisdiction;
- 20                (d) information in relation to a monitored medicine from an
- 21                approved data source entity;
- 22                (e) any other information prescribed by regulation.

- 1 **97E Monitored medicines database—chief health officer**  
2 **functions**
- 3 The chief health officer has the following functions in relation to the  
4 monitored medicines database:
- 5 (a) to collect and store required information about monitored  
6 medicines;
- 7 (b) to enter into an arrangement with another jurisdiction or an  
8 approved data source entity to—
- 9 (i) collect and store information for the database; and  
10 (ii) allow access to information on the database; and  
11 (iii) allow the use and disclosure of information on the  
12 database;
- 13 (c) to access and use the database to—
- 14 (i) monitor, promote and protect public health and safety;  
15 and  
16 (ii) facilitate research into the provision of healthcare; and  
17 (iii) administer, develop and operate the database; and  
18 (iv) ensure compliance with the Act;
- 19 (d) to allow access to, and the use and disclosure of, information  
20 on the database by a person mentioned in section 97F or  
21 section 97G (Monitored medicines database—access  
22 authority);
- 23 (e) any other function under this Act or another territory law.
- 24 *Note* A provision of a law that gives an entity (including a person) a function  
25 also gives the entity powers necessary and convenient to exercise the  
26 function (see [Legislation Act](#), s 196 and dict, pt 1, def *entity*).



---

1 **97F Monitored medicines database—access and use by**  
2 **relevant health practitioners**

- 3 (1) A relevant health practitioner may access and use the monitored  
4 medicines database for 1 or more of the following purposes:
- 5 (a) to inform decisions in relation to the prescription or supply of a  
6 monitored medicine to a person under the relevant health  
7 practitioner's care;
  - 8 (b) to inform decisions in relation to the treatment or care of a  
9 person under the relevant health practitioner's care;
  - 10 (c) to disclose information about a person under the relevant  
11 health practitioner's care to that person;
  - 12 (d) to disclose information about a person under the relevant  
13 health practitioner's care to another health practitioner  
14 involved in the person's treatment or care;
  - 15 (e) a purpose prescribed by regulation.
- 16 (2) The chief health officer must make the monitored medicines  
17 database available to a relevant health practitioner at no cost.

18 **97G Monitored medicines database—access authority**

- 19 (1) A person, other than a relevant health practitioner, may apply to the  
20 chief health officer for authorisation to access and use the monitored  
21 medicines database (an *access authority*).

22 *Note 1* If a form is approved under s 198 for this provision, the form must be  
23 used.

24 *Note 2* A fee may be determined under s 197 for this provision.

- 25 (2) The chief health officer may issue the access authority only if  
26 satisfied that giving the access authority to the person is—
- 27 (a) consistent with a purpose of the monitored medicines database;  
28 and

- 1 (b) otherwise in the public interest.
- 2 (3) An access authority must—
- 3 (a) be in writing; and
- 4 (b) include the following information:
- 5 (i) the name of the person to whom the authority is issued;
- 6 (ii) the purpose for which the authority is issued;
- 7 (iii) any conditions applying to the authority;
- 8 (iv) the expiry date of the authority.

9 **97H Monitored medicines database—offences**

- 10 (1) A person commits an offence if—
- 11 (a) the person accesses information from the monitored medicines
- 12 database; and
- 13 (b) the access is not authorised under this chapter.
- 14 Maximum penalty: 30 penalty units.
- 15 (2) A person commits an offence if—
- 16 (a) the person accesses information from the monitored medicines
- 17 database; and
- 18 (b) the person uses the accessed information; and
- 19 (c) the use is not authorised under this chapter.
- 20 Maximum penalty: 50 penalty units.
- 21 (3) A person commits an offence if—
- 22 (a) the person accesses information from the monitored medicines
- 23 database; and

- 1 (b) the person discloses the accessed information to someone else;  
2 and  
3 (c) the disclosure is not authorised under this chapter.  
4 Maximum penalty: 50 penalty units.
- 5 (4) Strict liability applies to subsections (1) (a), (2) (a) and (3) (a).  
6 (5) In this section:  
7 *disclose*, in relation to information accessed from the monitored  
8 medicines database, includes—  
9 (a) communicate the information; or  
10 (b) publish the information.  
11 *use*, in relation to information accessed from the monitored  
12 medicines database, includes make a record of the information.

13 **6 Disciplinary action against authorisation holders**  
14 **Section 141 (1) (d)**

- 15 *omit*  
16 *varying*  
17 *substitute*  
18 *amending*

19 **7 New section 141 (1) (h)**

- 20 *insert*  
21 (h) if the authorisation holder is authorised to access and use the  
22 monitored medicines database—amending, suspending or  
23 cancelling the authority to access and use the database.

**8 Sections 144 (2) (b) and 145 (1) (b)**

2 *omit*

3 varied

4 *substitute*

5 amended

**9 Section 145 (1) (c)**

7 *omit*

8 variation

9 *substitute*

10 amendment

**10 Action by chief health officer in relation to certain  
licences and approvals  
Section 146 (1)**

14 *substitute*

15 (1) If a licence or approval amended under this part is returned to the  
16 chief health officer, the chief health officer must—

17 (a) amend the licence or approval and return it to the authorisation  
18 holder; or

19 (b) give the authorisation holder a replacement licence or approval  
20 that includes the amendment.

21 *Note* A licence or approval is taken to be amended if an authorised dealing  
22 under the licence or approval is suspended (see s 144 (2)).

1 **11 Reviewable decisions**  
2 **Schedule 1, item 6, column 3, 4th dot point**

3 *omit*

4 *vary*

5 *substitute*

6 *amend*

7 **12 Dictionary, new definitions**

8 *insert*

9 *another jurisdiction*, for chapter 6A (Monitored medicines  
10 database)—see section 97B.

11 *approved data source entity*, for chapter 6A (Monitored medicines  
12 database)—see section 97B.

13 *monitored medicine*—see section 97A.

14 *monitored medicines database*, for chapter 6A (Monitored  
15 medicines database)—see section 97B.

16 *relevant health practitioner*, for chapter 6A (Monitored medicines  
17 database)—see section 97B.

18 *required information*, about the supply of a monitored medicine, for  
19 chapter 6A (Monitored medicines database)—see section 31 (4).

1 **Part 3** **Medicines, Poisons and**  
2 **Therapeutic Goods**  
3 **Regulation 2008**

4 **13** **Section 81**

5 *substitute*

6 **81** **Information for CHO about monitored medicines supplied**  
7 **on supply authorities—Act, s 31 (1) (b) and (4), def**  
8 ***required information***

- 9 (1) A person (the *supplier*) who supplies a monitored medicine on a  
10 supply authority must, not later than 7 days after the day when the  
11 medicine is supplied, give the chief health officer the following  
12 information in writing:
- 13 (a) the supplier's name, business address and telephone number;
  - 14 (b) the name of the person who issued the supply authority;
  - 15 (c) the date of the supply authority;
  - 16 (d) the name, date of birth and address of the person to whom the  
17 medicine is supplied;
  - 18 (e) the date of supply;
  - 19 (f) the monitored medicine, and the form, strength and quantity of  
20 the medicine, supplied.
- 21 (2) However, this section does not apply to any of the following who  
22 report the supply of a monitored medicine on a supply authority to  
23 the Therapeutic Goods Administration:
- 24 (a) a medicines wholesalers licence-holder;

- 1 (b) a person who is authorised (however described) under a  
2 Commonwealth or State law to manufacture a monitored  
3 medicine or supply a monitored medicine by wholesale.

4 **14 Section 164**

5 *substitute*

6 **164 Information for CHO about monitored medicines supplied**  
7 **during consultations—Act, s 31 (2) (b) and (4), def**  
8 ***required information***

- 9 (1) This section applies if a prescriber supplies a monitored medicine  
10 for human use during a consultation.

11 *Note* **Supply** does not include administer (see [Act](#), s 24).

- 12 (2) The prescriber must, not later than 7 days after the end of the month  
13 when the monitored medicine is supplied, give the chief health  
14 officer the following information in writing:

- 15 (a) the prescriber's name, business address and telephone number;  
16 (b) the name, date of birth and address of the person to whom the  
17 medicine is supplied;  
18 (c) the date of supply;  
19 (d) the monitored medicine, and the form, strength and quantity of  
20 the medicine, supplied.

---

## Endnotes

**1 Presentation speech**

Presentation speech made in the Legislative Assembly on 10 May 2018.

**2 Notification**

Notified under the [Legislation Act](#) on 2018.

**3 Republications of amended laws**

For the latest republication of amended laws, see [www.legislation.act.gov.au](http://www.legislation.act.gov.au).

---

© Australian Capital Territory 2018